The Motley Fool

3 FTSE shares with big dividends I’d like to buy right now

Image source: Getty Images.

One strategy for constructing a long-term portfolio of shares involves focusing on the shareholder dividends companies pay. If I collect a large yield in income and plough the proceeds back into my shares, I’ll be compounding my investments.

Another benefit of focusing on the shareholder dividend is that big yields often indicate a modest valuation. So, if the annual dividend grows over time, there’s a good chance the share price will also rise and deliver capital growth in my portfolio as well.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

However, the strategy works best if I target sustainable dividends. So, I’ll avoid cyclical businesses and look for firms with strong finances operating in a profitable niche of the market, such as these three.


The recent bout of general stock market weakness has pushed down the share price of pharmaceuticals giant GlaxoSmithKline (LSE: GSK). It seems the company is out of favour with investors. One reason for that could be a general rotation out of defensive companies and into cyclical stocks that look poised for the next cyclical up-leg.

Indeed, although the likes of GlaxoSmithKline do operate cash-producing, defensive businesses, their valuations can move up and down in cycles. And right now, I think the valuation has cycled down.

And at the current share price near 1,350p, the dividend yield is just below 6%. Meanwhile, nobody expects much growth in earnings in the near term. But I do reckon the firm can keep up its dividend payments. For me, GlaxoSmithKline would make a decent long-term hold in my portfolio.

Power transmission

National Grid (LSE: NG), has a forward-looking dividend yield of just over 5% for the current trading year to March 2021. The guardian of the nation’s gas and electricity transmission networks has been a steady dividend payer for many years. And it’s clear the firm’s highly regulated monopoly position in the UK’s energy sector endows the business with defensive qualities.

The company also has operations in the US. And although National Grid carries a big debt load, the rock-solid cash generation it achieves makes sense of the high level of borrowings. However, the business requires large and continuous amounts of capital investment. And the directors must balance the cash flow returns to the company’s lenders and to its shareholders.

I don’t expect the business to ever shoot the lights out with growth. But I do think it’s capable of churning out those generous shareholder dividends for years to come.

Food additives

The food sector has defensive qualities and Tate & Lyle (LSE: TATE) is a big player in it. The company produces ingredients and solutions to the food, beverage and other industries, and it’s a lucrative market. We can see by the firm’s long record of paying generally rising shareholder dividends how well the cash keeps rolling in.

The share price has slipped back a bit this autumn and now stands near 612p. At that level, the forward-looking dividend yield for the current trading year to March 2021 is a little below 5%. Meanwhile, the company has already shown its resilience by trading well through the recent coronavirus lockdowns.

So, I’d treat a holding in the firm’s shares now as a sleep-at-night investment. And I’d hold with the tenacity of a business owner for at least the next 20 years.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.